These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 7654449)
41. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics. Zhou T; Kim Y; MacLeod AR Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493 [TBL] [Abstract][Full Text] [Related]
42. Antisense technology for cancer therapy: does it make sense? Carter G; Lemoine NR Br J Cancer; 1993 May; 67(5):869-76. PubMed ID: 8494718 [No Abstract] [Full Text] [Related]
46. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method. Yildiz D; Oztas H; Hilal Ates B Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566 [TBL] [Abstract][Full Text] [Related]
47. [Computer aid design of antisense oligonucleotide in gene therapy--review]. Wu QW; Wu JJ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):387-91. PubMed ID: 15228675 [TBL] [Abstract][Full Text] [Related]
49. Antisense '97: a roundtable on the state of the industry. Nat Biotechnol; 1997 Jun; 15(6):519-24. PubMed ID: 9181572 [No Abstract] [Full Text] [Related]
50. Therapeutic applications of spherical nucleic acids. Barnaby SN; Sita TL; Petrosko SH; Stegh AH; Mirkin CA Cancer Treat Res; 2015; 166():23-50. PubMed ID: 25895863 [TBL] [Abstract][Full Text] [Related]
51. Potential use of radiolabeled antisense oligonucleotides in oncology. Gauchez AS; Du Moulinet D'Hardemare A; Lunardi J; Vuillez JP; Fagret D Anticancer Res; 1999; 19(6B):4989-97. PubMed ID: 10697501 [TBL] [Abstract][Full Text] [Related]
52. Development of Antisense Drugs for Dyslipidemia. Yamamoto T; Wada F; Harada-Shiba M J Atheroscler Thromb; 2016 Sep; 23(9):1011-25. PubMed ID: 27466159 [TBL] [Abstract][Full Text] [Related]
53. [Perspectives of clinical oncology for the '90's]. Obrecht JP Onkologie; 1990 Oct; 13(5):333-6. PubMed ID: 2082227 [No Abstract] [Full Text] [Related]
54. New approaches in cancer pharmacology: drug design and development. Report of a European School of Oncology Task Force. Eur J Cancer; 1992; 28A(6-7):1190-200. PubMed ID: 1627393 [No Abstract] [Full Text] [Related]
55. Use of antisense vectors and oligodeoxynucleotides in neuro-oncology. Engelhard HH; Egli M; Rozental JM Pediatr Neurosurg; 1998 Jun; 28(6):279-85. PubMed ID: 9782204 [No Abstract] [Full Text] [Related]
56. Antisense therapy in malignant diseases: status quo and quo vadis? Tamm I Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947 [TBL] [Abstract][Full Text] [Related]
57. Antisense approaches to cancer gene therapy. Mercola D; Cohen JS Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254 [TBL] [Abstract][Full Text] [Related]
58. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects. Miyake H; Hara I; Fujisaw M; Gleave ME Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091 [TBL] [Abstract][Full Text] [Related]
59. Presentations from the 2nd NIH Symposium on Therapeutic Oligonucleotides: Targeting Transcription Factors and Signaling Pathways. Bethesda, Maryland, USA. December 5, 1997. Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):113-84. PubMed ID: 9669868 [No Abstract] [Full Text] [Related]
60. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth. Cho-Chung YS Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]